A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202;R-Roscovitine), administered twice daily for 7-days every 21 days.

View/Open

Published version (173.4Kb)

ICR Author

Raynaud, Florence

Workman, Paul

Kaye, Stanley Bernard

Author

Benson, C

White, J

De Bono, JS

O'Donnell, A

Raynaud, F

Cruickshank, C

McGrath, H

Frenz, L

Rose, F

Walton, M

Workman, P

Kaye, S

Show allShow less

Type

Journal Article

Metadata

Show full item record

URI

https://repository.icr.ac.uk/handle/internal/496

Collections

• Cancer Therapeutics
• Closed Research Teams

Research team

Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)

Medicine Drug Development Unit (Kaye)

Language

eng

Date accepted

2006-11-07

License start date

2006-11-07

Citation

Br J Cancer. 2007, Jan 15, 1 (96), pp. 29 - 37